Pandemic Perspectives: Cracks In Global Supply Chain Lead To Localization Trend
Regions Seek To Bolster Domestic Production Capacity As Weaknesses Exposed
Weaknesses in the global pharmaceutical supply chain, exposed and exacerbated by the coronavirus pandemic, have led major markets to pursue localization policies aimed at bolstering domestic production capacity. But any significant transformation promises to take many years.
You may also be interested in...
Headwinds as well as opportunities for the off-patent industry are discussed in a comprehensive new whitepaper by the International Generic and Biosimilar Medicines Association
A whitepaper setting out a comprehensive vision for the off-patent industry to 2030 has been launched by the IGBA. Highlighting the industry’s current contribution to healthcare, it also sets out a path ahead for the generics and biosimilars sector, pointing out headwinds as well as opportunities.
Sandoz CEO Richard Saynor has spoken of the ways in which the pandemic has changed the industry, from supply chains to working patterns, and makes predictions for the years ahead.